Articles tagged with Cancer Medication
Researchers found that patients receiving personalized cancer therapy had improved survival rates and longer progression-free periods compared to those with unmatched treatment plans. The use of next-generation sequencing allows for more precise targeting of cancer cells.
A recent study published in CA: A Cancer Journal for Clinicians found that little effort has been made to increase older adult participation in cancer clinical trials, despite the disproportionate impact of cancer on this age group. The researchers called for a more inclusive approach, recommending that trials ask targeted questions an...
The NeoALTTO BIG-06 trial found that women who achieved pathological complete response (pCR) after treatment had better long-term survival without cancer recurrence. Patients receiving both lapatinib and trastuzumab in combination also had a higher rate of pCR, resulting in improved overall survival rates.
The OU College of Medicine is launching a mobile classroom to promote diversity in health professions, aiming to recruit and retain students from rural and underserved areas. The grant-funded initiative will provide hands-on experience for young people across Oklahoma, particularly in smaller communities with limited resources.
A researcher at the University of Oklahoma is conducting a study to investigate the role of menthol flavoring in smoking habits among young adults. The study aims to inform the FDA's decision on whether to ban menthol flavoring in cigarettes, which could reduce smoking rates among at-risk populations.
The Mark Foundation has launched a new funding program for novel cancer therapeutics. Two projects have been selected, focusing on Ewing sarcoma and leukemias, targeting USP7 and CBP/p300 enzymes with highly selective inhibitors.
Researchers found that changing gene expression first can improve the effectiveness of immunotherapies in battling aggressive pancreatic cancer. The study suggests a promising approach by administering an epigenetically-acting drug before immune checkpoint inhibition, doubling average survival time in preclinical models.
Researchers at University of Würzburg developed a drug that can disarm Aurora-A kinase, a protein that causes extensive damage in cancers like leukemias and neuroblastomas. The new PROTAC substance completely degrades the Aurora protein in cancer cells, leading to cell death.
Researchers at UT Health San Antonio discovered that childhood chemotherapy changes the function of cells that repair heart injury, leading to increased risk of heart failure in survivors. The study found that damage to these cells may contribute to late effects seen in childhood cancer survivors when they become adults.
A repeated testing protocol for COVID-19 among patients with cancer was examined in a quality improvement study. The study found that asymptomatic cancer patients can be safely screened for COVID-19 without increasing the risk of infection.
A new study suggests that the gut microbiome plays a role in how prostate cancer patients respond to oral therapies like abiraterone acetate. The research found that bacteria in the gut metabolize the drug, leading to an increase in beneficial organisms with anti-cancer properties.
A clinical trial of selpercatinib has shown promising results for patients with non-small cell lung cancer, achieving high response rates and prolonged survival. The drug specifically targets cancers driven by mutations in the gene RET, with minimal side effects.
Researchers developed a framework to study metabolic processes in cancer cells using Raman spectroscopy and microscopy. The technique identified fatty acid synthesis and mono-unsaturation as new metabolic susceptibilities in cancer cells.
Genetic testing is cost-effective for newly diagnosed metastatic GIST patients, enabling clinicians to prescribe tumor-specific chemotherapy. This approach avoids ineffective treatment and reduces disease progression rates.
A new ATR inhibitor, BAY1895344, showed promising clinical benefits in a phase I trial for patients with advanced solid tumours and defects in genes that coordinate DNA repair. The drug was well-tolerated and stopped tumour growth in over half of patients.
Scientists at UNC Lineberger Comprehensive Cancer Center have identified CDR1as, a circular RNA, as a key player in driving metastasis in lung squamous cell cancer. By targeting this molecule, researchers believe it may be possible to develop new treatments with fewer side effects.
Researchers develop a nano-carrier for medications that can control release in diseased cells only. Synthetic DNA structures stabilize the particles and can be triggered by microRNA molecules found in cancer cells.
TMDU researchers have engineered a material that can identify and target cancer cells using an antibody-supermolecule conjugate, potentially overcoming drug resistance. The new approach showed enhanced autophagic cell death with lower concentrations of the treatment.
A Mayo Clinic study reveals that lung transplant patients who receive antifungal preventive medications have a significantly lower risk of death within the first year posttransplant. The study analyzed data from 667 patients and found that mortality risk was about twice as high in those not receiving treatment.
The study provides a comprehensive analysis of current clinical trials in pancreatic cancer, revealing that most trials focus on immunotherapy, chemotherapy, and radiation. The authors conclude that these approaches have yet to strongly impact the disease, emphasizing the need for new discoveries and biomarkers.
Researchers at NTU Singapore have devised a novel approach to kill cancer cells using a nanoparticle coated with an amino acid that selectively targets and destroys cancer cells. The 'Trojan horse' nanoparticle, called Nano-pPAAM, was tested in lab experiments and found to be effective in killing cancer cells with high specificity.
A computational pipeline predicts tumour response to different cancer treatments by identifying complex response markers from the patterns of co-occurrence between cancer driver genes. The system achieved 66% accuracy in predicting responses, offering a key factor in precision medicine for patients.
Scientists at UT Austin identified a protein that promotes DNA damage in BRCA 1/2-mutated cancer cells, making them resistant to PARP inhibitors. The finding may help create more effective treatment plans for patients with these cancers.
Scientists uncover how pomalidomide reduces cancer cell growth by breaking down the protein ARID2, promoting MYC gene expression. This finding provides a plausible explanation for pomalidomide's efficacy in treating lenidomide-resistant multiple myeloma.
A Rutgers study found that college students with disabilities are more likely to misuse prescription pain relievers and have a higher prevalence of drug use disorder. The study also highlights the need for healthcare providers to be aware of the risk of drug misuse in this population.
A VCU study reveals an experimental cancer drug called AR-12 may be effective against SARS-CoV-2, inhibiting viral infection and replication. The oral treatment has shown promise in previous studies, including against other viruses like Zika and influenza.
A phase 1 clinical trial of sotorasib (AMG 510) demonstrated anti-cancer activity in patients with heavily pretreated advanced solid tumors. Patients with non-small cell lung cancer had a 32% response rate and median progression-free survival of 6.3 months.
A major trial shows olaparib, a PARP inhibitor, is more effective than modern hormone treatments in slowing down prostate cancer growth and spread. Patients with genetic alterations in DNA repair genes who received olaparib had a median overall survival of 19.1 months.
A phase III clinical trial led by Queen Mary University of London shows that immunotherapy drug avelumab significantly improves survival in patients with the most common type of bladder cancer. Avelumab resulted in a 31% reduction in risk of death and extended median survival by over seven months.
Scientists have identified enzymes ASB13 and USB20 that regulate the recycling of a dangerous protein called SNAI2, which helps cancers metastasize. Targeting these enzymes may provide a way to control SNAI2's aggressiveness and prevent cancer progression.
A study presented at ESMO 2020 found significant variations in access to cancer medicines and clinical trials across European countries. Western European nations tend to have more clinical trials, while Eastern and Central European countries face barriers due to limited infrastructure and resources.
Researchers found a sixfold variation in itraconazole levels in tumor samples of lung cancer patients treated with the drug at a fixed dose. The levels correlated with tumor shrinkage and growth inhibition. Higher blood and tumor levels led to greater decreases in tumor volumes and reductions in new blood vessel formation.
A $11.4 million NIH grant has funded the advancement of a novel drug candidate, SBP-9330, targeting a neuronal signaling pathway underlying addictive behaviors to treat nicotine addiction. The drug is expected to be effective in reducing nicotine self-administration and may broaden its indication to other types of addiction.
A team of scientists has unraveled the molecular basis underlying colorectal cancer by discovering how mutations in RNF43 activate the Wnt signaling pathway. This finding provides potential treatment options for certain types of colorectal cancer.
Researchers at Babraham Institute used cellular signalling knowledge to discover ERK5 protein's binding location affects inhibitors, potentially leading to unwanted cell growth. This finding prevents wasted resource in commercial pharmaceutical companies' drug discovery efforts.
Smokers have worse chemotherapy response and higher mortality rates from bladder cancer, with a higher risk of cancer recurrence. Former smokers also fare poorly in these categories.
A preclinical study from MD Anderson and BridgeBio's Navire Pharma shows that SHP2 inhibition can overcome osimertinib resistance in lung cancer. The study found that IACS-13909 suppressed tumor cell proliferation and caused tumor regression in various activated kinase-driven models.
Researchers found a combination of olaparib and capivasertib to be effective against advanced cancers, including those that stopped responding to chemotherapy. The treatment targets two weaknesses in cancer, DNA repair and AKT addiction, offering new hope for patients with drug-resistant cancer.
Researchers found that patients on immunosuppressive therapy are not at increased risk for contracting COVID-19. In fact, some medications may even lower hospitalization rates. However, multiple medication regimens may increase susceptibility to the virus.
A new UCLA study identifies two key drivers of the immune system's attack on cancer cells: T cell infiltration and interferon-gamma signaling. The research found that blocking immune checkpoints amplifies interferon-gamma signaling, leading to enhanced antitumor immune responses.
A new study from Northwestern Medicine reveals that biological sex has a small but significant impact on gene expression in every type of human tissue. The researchers found over 37% of genes were expressed differently in males and females, with diverse molecular functions involved, including disease-related traits.
Researchers developed DNA-based nanovaccines that stimulate killer T cell immunity, resulting in tumor control. The synthetic vaccines enhanced CD8 T cell activation and induced muscle cell apoptosis, attracting macrophage infiltration and activating immune responses.
A major clinical trial found that a blood test can reliably match women with advanced breast cancer to effective targeted treatments by tracking disease evolution and mutations. The plasmaMATCH trial showed promising results, validating the use of liquid biopsies in routine care for patients with rare subtypes of breast cancer.
Drs. Dennis Lo, Karen Mann and Ronald Przygodzki are recognized for their pioneering work in non-invasive prenatal testing and cancer detection using circulating nucleic acids. Their innovations have created a paradigm in prenatal medicine and advanced the field of molecular diagnostics.
Researchers at City of Hope found that Andrographis paniculata, a natural botanical, is effective in killing chemo-resistant colon cancer cells when used in conjunction with chemotherapy. The study's goal was to develop a non-toxic treatment that could succeed in killing cancer cells.
A new drug developed by University of Sheffield researchers could block signals from a hormone that helps cancer cells grow and spread, potentially improving life expectancy and quality of life for pancreatic cancer patients. The compound targets a specific receptor in cancer cells without affecting vital bodily processes.
A retrospective study from George Washington University found that spironolactone is not associated with increased risk of female breast cancer recurrence. The drug may be used as an additional treatment option for alopecia in female breast cancer patients who are disease-free.
Researchers found that 27% of immune checkpoint inhibitor recipients experienced irAEs, with 5% developing multi-organ irAEs sequentially. Multi-organ irAEs were generally amenable to satisfactory management and associated with better overall survival rates.
Researchers developed a novel drug delivery system that significantly enhances the effectiveness of treatment for melanoma. The system uses a biocompatible and biodegradable polymer to deliver two proven medications simultaneously at the tumor site, resulting in longer-lasting therapeutic effects and lower dosages.
A study analyzing nearly 900 kidney cancer patients identified novel biomarkers and gene signatures associated with treatment response. These findings could help personalize treatments for patients based on their individual tumor characteristics.
Researchers develop a hydrogel-based delivery system that releases an anti-rejection drug slowly over time, providing enhanced protection for transplanted hearts. The system, called MTH, was shown to improve graft survival rates and reduce immune response.
Researchers at UT Southwestern Medical Center have discovered two experimental drugs that can suppress the growth and spread of non-small cell lung cancer (NSCLC) by affecting its blood vessels, oxygen levels, and other environmental factors. The findings highlight the potential of these drugs for NSCLC treatment.
A large study of over 260,000 participants found no evidence that blood pressure lowering drugs increase the risk of cancer. The research analyzed data from 31 trials and investigated five antihypertensive drug classes, including ACE inhibitors and beta blockers.
A study published in Scientific Reports found that life expectancy for Black men in Washington, DC, was on average 17.23 years shorter than for white men, while Black women had a gap of 12.06 years. The study attributed these disparities to factors such as heart disease, homicide, cancer, and socioeconomic conditions.
A new breast cancer treatment developed by UIC researchers has shown safety and effectiveness in Phase 1 clinical trials, with no toxic side effects reported. The drug, TTC-352, halted disease progression in six patients with metastatic breast cancer, offering a promising alternative to traditional hormone therapy.
Researchers at Baylor College of Medicine developed an improved type of PROTAC that enhances intracellular accumulation and functions, not only as a degrader but also as an inhibitor of the target protein. The study's findings suggest the possibility of applying this strategy to improve PROTACs for clinical applications.
A majority of patients with medullary thyroid cancer treated with selpercatinib lived for more than a year without disease progression. The drug showed high efficacy and good tolerability, with response rates of up to 79% and manageable side effects.
Researchers developed a world-first technique to improve cancer treatments by analyzing fresh patient tumour biopsies within 30 minutes of collection. The 'Drug uptake in ex Vivo tumours' technique helps pharmaceutical and technology companies design future cancer drugs.
Researchers adapted principles of quantum control to calculate alternative interventions for infection and cancer. They developed a mathematical algorithm that can design and speed up specific interventions to prevent or overturn drug resistance, offering a promising approach to defeating drug-resistant diseases.
The European Society for Medical Oncology has issued its first recommendations on the use of next-generation sequencing (NGS) for patients with metastatic cancers. The guidelines recommend routine NGS use for four specific cancer types, while also allowing patients to order larger gene panels if feasible and cost-effective. The recomme...